Noticias BELLUS Health Inc - BLU | Acciones Toronto Stock Exchange | ADVFN

US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

Inicio
Invertir
Acciones
Canadá
TSX
BELLUS Health Inc (BLU)
BELLUS Health Inc (BLU) Noticias

BELLUS Health Inc (BLU)

19.48

0.00

(0.00%)

Cerrado 21 Abril 3:12PM

Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel...

BELLUS Santé participera prochainement à plusieurs conférences pour les investisseurs

BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe...

BELLUS Santé participera à la Cowen & Co. 42nd Annual Health Care Conference

BELLUS Santé inc. (Nasdaq : BLU; TSX : BLU) (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe...

BELLUS Santé annonce ses résultats financiers et faits saillants pour l’exercice 2021

- Annonce des résultats principaux positifs de l’essai clinique SOOTHE de phase 2b pour le traitement de la toux chronique réfractaire qui...

BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States

BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced...

BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

Common Shares Priced at US$8.00 per Share In connection with its previously announced public offering of common shares in Canada and the United...

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States

BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement...

BELLUS Santé annonce les principaux résultats positifs de son essai SOOTHE de phase 2b du BLU-5937 pour le traitement de la toux chronique réfractaire

Le principal critère d’évaluation de l’efficacité est statistiquement significatif, une réduction de 34 % de la fréquence de toux sur une période...

Error: 507

mik1234

mik1234 4 años hace

it was a good day $$ BLU

Oliverjack

Oliverjack 5 años hace

insider bought 260k worth today monday 13th lol

Bottom Feedr

Bottom Feedr 5 años hace

Massive drop and ceo buys more! Hmmnnnn

Bottom Feedr

Bottom Feedr 5 años hace

Wake up sleepy head time to rock the market!

dalesio_98

dalesio_98 6 años hace

RichardSawars

RichardSawars 6 años hace

TrendTrade2016

TrendTrade2016 7 años hace

BLU.TO hot canadian bio

TrendTrade2016

TrendTrade2016 7 años hace

BLU is a beast!!

TrendTrade2016

TrendTrade2016 7 años hace

The BLU beast!!

TrendTrade2016

TrendTrade2016 7 años hace

put out a call on BLU.TO a monster bio play!!

xr_biotech_consult

xr_biotech_consult 9 años hace

happy to sold nearly 8000 during last days...only 4000 left for sale today.

xr_biotech_consult

xr_biotech_consult 9 años hace

2.99 weeeeEEEE°°

xr_biotech_consult

xr_biotech_consult 9 años hace

what shoud i say? 2.32 !!

xr_biotech_consult

xr_biotech_consult 9 años hace

xr_biotech_consult

xr_biotech_consult 9 años hace

yessss..new high..1.92

xr_biotech_consult

xr_biotech_consult 9 años hace

great Chart.. crushed 1,75 good sign. more will come

xr_biotech_consult

xr_biotech_consult 9 años hace

pivotal Phase 3 trail completed, top line results expected q2, fast track by FDA, rare desease, Long patent protection, Peak sales expected -1b ! ongoing Pipeline with rare deseases.. still great opportunity here

xr_biotech_consult

xr_biotech_consult 9 años hace

xr_biotech_consult

xr_biotech_consult 9 años hace

hrhr here weee goo

xr_biotech_consult

xr_biotech_consult 9 años hace

expected Prices per Patient per year 200-275 Thousand

xr_biotech_consult

xr_biotech_consult 9 años hace

Peak sales expected 600m - 1b
http://www.bellushealth.com/English/investors-and-news/presentations/default.aspx

xr_biotech_consult

xr_biotech_consult 9 años hace

xr_biotech_consult

xr_biotech_consult 10 años hace

will move up again

xr_biotech_consult

xr_biotech_consult 11 años hace

target 2.50 CAD

xr_biotech_consult

xr_biotech_consult 11 años hace

yea hell great, new high hunts new high

xr_biotech_consult

xr_biotech_consult 11 años hace

BLU out in the blue

xr_biotech_consult

xr_biotech_consult 11 años hace

waht did i told u

xr_biotech_consult

xr_biotech_consult 11 años hace

massive breakout will come here

Travelsky Technology

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones